{
    "clinical_study": {
        "@rank": "116096", 
        "arm_group": {
            "arm_group_label": "children born from HIV-HBV women", 
            "description": "Studying retrospectively their status for HBs Ag and HBc Ab"
        }, 
        "brief_summary": {
            "textblock": "Vertical HIV transmission has been dramatically reduced by the use of combined\n      antiretroviral therapy in HIV-infected pregnant women. Among the most often used drugs,\n      several have dual activity, against HIV and HBV: lamivudine, emtricitabine, tenofovir.\n      Studies about vertical HBV transmission from HIV-HBV co-infected pregnant women are rare in\n      developed countries. The study hypothesis is a major reduction of the risk of HBV vertical\n      transmission."
        }, 
        "brief_title": "Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Vertical Disease Transmission", 
            "HBV"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "detailed_description": {
            "textblock": "Mother-to-Child HIV transmission has been dramatically reduced by the use of combined\n      antiretroviral therapy in HIV-infected pregnant women, both in developed and in developing\n      countries. Among the most often used drugs, several have dual activity, against HIV and HBV:\n      lamivudine, emtricitabine, tenofovir; they can be used as a combo, as\n      tenofovir+emtricitabine for instance. Studies about vertical HBV transmission from HIV-HBV\n      co-infected pregnant women are rare in developed countries. The study hypothesis is a major\n      reduction of the risk of HBV vertical transmission in this context, justifying this\n      retrospective study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  children born in the Maternity Department from HIV-HBV co-infected women\n\n          -  whose mother was given a treatment with dual activity (HIV and HBV) during pregnancy\n\n        Exclusion Criteria:\n\n          -  no"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "9 Months", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All children born in the Maternity Department, Lariboisiere Hospital, Paris, France, from\n        HIV-HBV co-infected women"
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044068", 
            "org_study_id": "Liver003"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "contact": {
                "email": "pierre.sellier@lrb.aphp.fr", 
                "last_name": "Pierre O SELLIER, MD, PhD", 
                "phone": "00 33 149956339"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75475"
                }, 
                "name": "Hopital Lariboisiere"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prevention of Hepatitis B Virus Mother-to-Child Transmission (MTCT) From HIV-HBV Co-infected Pregnant Women by Use of Nucleosides/Nucleotides Analogues With Dual Activity During Pregnancy.", 
        "overall_contact": {
            "email": "pierre.sellier@lrb.aphp.fr", 
            "last_name": "Pierre O SELLIER, MD, PhD", 
            "phone": "00 33 149956339"
        }, 
        "overall_official": {
            "affiliation": "Hopital Lariboisiere, Paris, France", 
            "last_name": "Pierre O SELLIER, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Hepatitis B sAg status in children born from HIV-Hepatitis B Virus co-infected women", 
            "safety_issue": "No", 
            "time_frame": "up to 10 years (expected average: 5 years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044068"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hopital Lariboisi\u00e8re", 
            "investigator_full_name": "Stephane Mouly, MD PhD", 
            "investigator_title": "Professor at Paris VII Denis Diderot University, physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Antibodies (Ab) against Hepatitis B core antigen in children", 
            "safety_issue": "No", 
            "time_frame": "up to 10 years (expected average: 5 years)"
        }, 
        "source": "Hopital Lariboisi\u00e8re", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hopital Lariboisi\u00e8re", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}